Biotech Values

[randychub]

David - This my be true but it is a long way off. There could well be other improvements in cancer drugs before this ever happens.

"If "nimo's" efficacy in early trials is confirmed in pivotal trials, both Erbitux and p-mab will be abandoned by the marketplace"

I believe there are over 100 erbitux trials in process. There is a handful of nimo trials being executed and only for niche areas of the market. Your talking 5-7 years down the road here.

I own YMI and IMCL and I agree on the current valuation. If Imclone is not bought out and CRC first line data or NSCLC is up to par with Avastin things will certainly change.

Randy